Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

360
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

169
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

1

Information Journal Paper

Title

Management of Refractory/RelapsedAcute Leukemia with Heart Limitation byAnthracycline-free ChemotherapyRegimens in Pediatric Patients: NewHypothesis and New Approach

Pages

  77-84

Abstract

 Background: Anthracycline therapy for Acute leukemia may be associated withsignificant morbidity and mortality in children or elderly patients that have a degreeof heart failure. Patients with prior anthracycline exposure, those with pre-existingheart disease, or who have received the total anthracycline dose present an increasedrisk for cardiotoxicity. Therefore, new Chemotherapy regimens in these situations wouldbe life saving for leukemia patients. We have conducted a systematic review of possiblestrategies for rescue regimens without anthracycline in refractory Acute leukemiapatients. Methods: We gathered the data from 5 creation databases and relevant websiteuntil August 2016. We selected randomized clinical trials or other studies that usedanthracycline-free Chemotherapy regimens to treat acute refractory leukemia inchildren and adults. The quality of the studies was evaluated according to theCochrane risk of the polarization tool. All stages of the review were independentlyconducted by two authors. We obtained data from 75 main clinical trials. Results: There were 75 trials included from which 4 were considered to be at lowrisk for bias. Most trials showed that the improvement did not reach statisticalsignificance. Conclusion: Evidence existed to support the use of the combination of fludarabine, cytarabine, and filgrastim, ICE-rituximab Chemotherapy regimens, or monoclonalantibodies such as tyrosine kinase inhibitors (Sorafenib) useful for acuterefractory/relapsed leukemia. These drugs are used as first salvage regimens orclofarabine and cladribine for acute myeloid leukemia in patients for whom combinedanthracycline Chemotherapy is inappropriate.

Cites

References

  • No record.

    • Cite

    APA: Copy

    ABDOLKARIMI, BABAK, ZAREIFAR, SOHEILA, KARIMI, MEHRAN, & Salajegheh, Pouria. (2018). Management of Refractory/RelapsedAcute Leukemia with Heart Limitation byAnthracycline-free ChemotherapyRegimens in Pediatric Patients: NewHypothesis and New Approach. MIDDLE EAST JOURNAL OF CANCER, 9(2), 77-84. SID. https://sid.ir/paper/321231/en

    Vancouver: Copy

    ABDOLKARIMI BABAK, ZAREIFAR SOHEILA, KARIMI MEHRAN, Salajegheh Pouria. Management of Refractory/RelapsedAcute Leukemia with Heart Limitation byAnthracycline-free ChemotherapyRegimens in Pediatric Patients: NewHypothesis and New Approach. MIDDLE EAST JOURNAL OF CANCER[Internet]. 2018;9(2):77-84. Available from: https://sid.ir/paper/321231/en

    IEEE: Copy

    BABAK ABDOLKARIMI, SOHEILA ZAREIFAR, MEHRAN KARIMI, and Pouria Salajegheh, “Management of Refractory/RelapsedAcute Leukemia with Heart Limitation byAnthracycline-free ChemotherapyRegimens in Pediatric Patients: NewHypothesis and New Approach,” MIDDLE EAST JOURNAL OF CANCER, vol. 9, no. 2, pp. 77–84, 2018, [Online]. Available: https://sid.ir/paper/321231/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top